📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Aarti Drugs to Invest ₹10 Crore in Subsidiary Pinnacle Life Science for Expansion
Aarti Drugs Limited has approved an investment of ₹10 crore in its wholly-owned subsidiary, Pinnacle Life Science Private Limited, through a rights issue. The capital infusion is specifically intended to finance Pinnacle's expansion and capital expenditure plans, alongside general corporate purposes. Pinnacle is a key formulations player for the group, exporting to over 30 countries, though its turnover saw a decline to ₹253.92 crore in FY25 from ₹314.66 crore in FY24. This investment signals the parent company's commitment to strengthening its formulations business segment.
Key Highlights
Investment of ₹10 crore via subscription to 78,125 equity shares at a price of ₹1,280 per share (including premium).
Pinnacle Life Science reported a turnover of ₹253.92 crore for FY 2024-25.
Funds will be utilized for financing expansion/capex plans and general corporate purposes.
Pinnacle operates in high-growth segments including oncology, cardiovascular, anti-infectives, and diabetics.
The share allotment is expected to be completed on or before March 20, 2026.
💼 Action for Investors
Investors should view this as a strategic move to bolster the formulations subsidiary, though they should monitor if this capex helps reverse the recent decline in Pinnacle's annual turnover.
Aarti Drugs Q3 FY26: PAT Surges 58% to ₹40.5 Cr Despite EBITDA Margin Pressure
Aarti Drugs reported a mixed performance for Q3 FY26, with consolidated revenue growing 8% YoY to ₹602.9 crores and PAT surging 58% to ₹40.5 crores. However, EBITDA declined 10% YoY to ₹56.3 crores with margins contracting to 9.3% due to weak antibiotic demand, supply chain disruptions from China, and one-time plant shutdowns for refurbishment. The formulations segment was a bright spot, growing 58% YoY, driven by strong export demand. Management expects significant margin improvement as the new Sayakha facility ramps up from 30% to 50% utilization by April 2026.
Key Highlights
Consolidated revenue increased 8% YoY to ₹602.9 crores, while PAT rose 58% to ₹40.5 crores.
Formulations segment revenue grew 58% YoY to ₹76.6 crores, with exports accounting for 67% of segment sales.
The Sayakha greenfield facility achieved 30% utilization in its first quarter, targeting 50% by April 2026.
Operational headwinds including plant shutdowns and ramp-up costs impacted PBT by approximately ₹14-15 crores.
First oncology product commercialization is scheduled for Q4 FY26, with oncology expected to contribute 40% of formulation revenue in 3 years.
💼 Action for Investors
Investors should focus on the successful ramp-up of the Sayakha facility and the commercialization of the oncology pipeline in Q4 as key triggers for margin recovery. While short-term margins are under pressure, the backward integration strategy is expected to add ₹50 crores to annual EBITDA at full scale.
Aarti Drugs Q3 FY26: PAT Jumps 58% YoY to ₹40.5 Cr; EBITDA Margins Contract to 9.3%
Aarti Drugs reported a mixed Q3 FY26 with revenue growing 8% YoY to ₹602.9 crore, led by strong growth in Formulations (+59%) and Specialty Chemicals (+51%). While PAT surged 58% YoY to ₹40.5 crore, operational EBITDA declined 10% YoY to ₹56.3 crore due to commissioning costs of new facilities and transient market dynamics. The company is aggressively pursuing backward integration, with its new Sayakha plant achieving 30% utilization and aiming for 100% self-reliance in Metformin intermediates within 8 months. Management indicates that pricing has reached an inflection point with improved momentum seen in January 2026.
Key Highlights
Consolidated Revenue grew 8% YoY to ₹602.9 crore, though API segment revenue slightly declined by 1% YoY.
EBITDA margins contracted by 190 bps YoY to 9.3% due to initial absorption of commissioning costs.
Formulations segment revenue rose 59% YoY to ₹76.4 crore, with exports accounting for 67% of this segment.
Sayakha plant for methyl amines achieved 30% capacity utilization in its first quarter of operations.
9M FY26 PAT stands at ₹139.7 crore, reflecting a 49% YoY growth compared to the previous year.
💼 Action for Investors
Investors should monitor the capacity ramp-up at the Sayakha and Tarapur facilities, as successful backward integration is key to margin recovery. While the YoY PAT growth is strong, the QoQ decline in EBITDA suggests operational pressures that need to stabilize in the coming quarters.
Aarti Drugs Q3 FY26: Revenue Up 8% to ₹603 Cr, PAT Surges 58% Aided by Tax Refund
Aarti Drugs reported a steady 8% YoY revenue growth to ₹602.9 crore for Q3 FY26, driven by domestic demand and export formulations. While PAT surged 58% to ₹40.5 crore, this was significantly bolstered by a ₹16.38 crore income tax refund. Operational performance faced pressure as EBITDA fell 10% YoY to ₹56.3 crore, with margins contracting to 9.3% due to high-cost inventory consumption and temporary maintenance shutdowns. The company is making strategic progress in backward integration, with its new Sayakha facility reaching 30% capacity utilization in its first quarter.
Key Highlights
Consolidated revenue grew 8% YoY to ₹602.9 crore, while 9M FY26 revenue reached ₹1,846.6 crore.
EBITDA margins contracted by 190 bps YoY to 9.3% due to inventory-related factors and scheduled maintenance.
PAT increased 58% YoY to ₹40.5 crore, inclusive of a one-time IT tax refund of ₹16.38 crore.
Sayakha backward integration plant achieved 30% capacity utilization; expected to reach 50% by April 2026.
API segment continues to dominate the revenue mix at 75.5%, followed by Formulations at 12.7%.
💼 Action for Investors
Investors should monitor the ramp-up of the Sayakha and Tarapur facilities, as successful backward integration is critical for margin recovery. While the PAT growth looks high, it is heavily influenced by a tax refund, so focus should remain on core EBITDA improvements in upcoming quarters.
Aarti Drugs Q3 Net Profit Rises 9.3% YoY to ₹40.55 Cr; Declares ₹2 Interim Dividend
Aarti Drugs reported a consolidated net profit of ₹40.55 crore for Q3 FY26, marking a 9.3% growth compared to ₹37.09 crore in the same period last year. Revenue from operations increased 8.1% YoY to ₹601.71 crore, although it saw a sequential decline from ₹652.79 crore in Q2. The company declared an interim dividend of ₹2 per share (20%) with a record date of February 9, 2026. Additionally, the company strengthened its leadership by inducting three functional heads into the Senior Management Personnel category to align with organizational growth.
Key Highlights
Consolidated Net Profit for Q3 FY26 stood at ₹40.55 crore, up from ₹37.09 crore YoY.
Revenue from operations grew 8.1% YoY to ₹601.71 crore for the quarter ended December 31, 2025.
Declared an interim dividend of ₹2 per equity share with a record date fixed for February 9, 2026.
9M FY26 consolidated net profit reached ₹140.54 crore on a total revenue of ₹1,845.01 crore.
New manufacturing plant at Sayakha, Gujarat, which commenced operations in Sept 2025, is now contributing to production.
💼 Action for Investors
Investors may view the YoY growth and dividend declaration positively, though the sequential dip in revenue suggests monitoring margin pressures. Focus on the scaling of the new Sayakha plant as a primary growth catalyst for the upcoming quarters.
Aarti Drugs Declares Rs 2 Interim Dividend; Sets February 9 as Record Date
Aarti Drugs Limited has announced an interim dividend of Rs 2 per equity share for the financial year 2025-26, representing a 20% payout on the face value of Rs 10. The Board of Directors approved this distribution during their meeting on February 3, 2026. The company has officially designated February 9, 2026, as the record date to identify shareholders eligible for the payment. This move reflects the company's commitment to sharing profits with its investors.
Key Highlights
Interim dividend of Rs 2 per equity share declared for FY 2025-26
Dividend payout represents 20% of the face value of Rs 10 per share
Record date for dividend eligibility fixed as February 9, 2026
Board meeting for the declaration was held on February 3, 2026
💼 Action for Investors
Investors seeking to receive the dividend should ensure they hold the shares before the ex-dividend date, typically one business day prior to the record date. Long-term investors may view this consistent payout as a sign of stable cash flow.
Aarti Drugs Declares ₹2 Interim Dividend; Q3 Net Profit Rises 9.4% YoY to ₹40.54 Cr
Aarti Drugs has declared an interim dividend of ₹2 per share for FY 2025-26, setting February 9, 2026, as the record date. The company reported a consolidated net profit of ₹40.54 crore for Q3 FY26, representing a 9.4% growth year-on-year, though it saw a sequential decline from ₹45.16 crore in Q2. Revenue for the quarter stood at ₹601.71 crore, up 8.1% from the previous year's corresponding quarter. Additionally, the company highlighted the commencement of its new manufacturing plant in Sayakha, Gujarat, which began operations in September 2025.
Key Highlights
Declared interim dividend of ₹2 per equity share (20% of face value) with a record date of February 9, 2026.
Consolidated Q3 FY26 revenue reached ₹601.71 crore, an 8.1% increase over Q3 FY25.
Net profit for the quarter grew 9.4% YoY to ₹40.54 crore, while EPS stood at ₹4.44.
New manufacturing plant at Sayakha, Gujarat, successfully commenced commercial operations on September 4, 2025.
Strengthened leadership by appointing three new functional heads to the Senior Management Personnel team.
💼 Action for Investors
Investors should track the record date of February 9 to be eligible for the dividend and monitor the performance of the new Sayakha plant for its impact on future margins. While YoY growth is steady, the sequential decline in revenue and profit suggests a need to watch for cost pressures in the pharmaceutical segment.
Aarti Drugs Q3 Net Profit Rises 9.4% YoY to ₹40.5 Cr; Declares ₹2 Interim Dividend
Aarti Drugs reported a consolidated revenue of ₹601.7 crore for Q3 FY26, marking an 8.1% growth compared to ₹556.6 crore in the same period last year. Net profit for the quarter increased to ₹40.5 crore from ₹37.1 crore YoY, although it saw a sequential decline from ₹45.2 crore in Q2 FY26. The company declared an interim dividend of ₹2 per share (20%) with a record date of February 9, 2026. Performance was supported by the commencement of the new Sayakha, Gujarat plant earlier in the fiscal year.
Key Highlights
Consolidated Revenue from operations stood at ₹601.7 crore, up 8.1% YoY but down 7.8% QoQ.
Net Profit for the quarter reached ₹40.5 crore, a 9.4% increase over the previous year's ₹37.1 crore.
Interim dividend of ₹2 per equity share declared with a total payout of approximately ₹18.25 crore.
New manufacturing facility at Sayakha, Gujarat, which started in September 2025, is now contributing to operations.
Three functional heads in Marketing, Export Marketing, and Purchase elevated to Senior Management Personnel.
💼 Action for Investors
Investors may find the YoY growth and dividend declaration encouraging, though the sequential dip in profitability suggests monitoring margin pressures. Focus should remain on the volume ramp-up from the new Sayakha plant in the upcoming quarters.